A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants

Study Identifier:
ACH471-011
ClinicalTrials.gov Identifier:
NCT03384186
EudraCT Identifier:
2017-003525-15
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: Danicopan Modified Release Prototype 1
  • Drug: Danicopan Modified Release Prototype 2
  • Drug: Danicopan Modified Release Prototype 3
Date
Dec 2017 - Mar 2018
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years
Requirements Information
Sex
Female & Male
Age
18 - 55 Years

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: Danicopan Modified Release Prototype 1
  • Drug: Danicopan Modified Release Prototype 2
  • Drug: Danicopan Modified Release Prototype 3
Date
Dec 2017 - Mar 2018
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years years
Requirements Information

Protocol Summary

The purpose of this study was to evaluate and compare the plasma pharmacokinetic profiles of ACH-0144471 (danicopan) in healthy participants after administration of single oral doses of modified release prototype formulations.

Trial Locations

Location
Status
Location
Clinical Trial Site
Ruddington, Nottingham, United Kingdom, NG111 6JS
Status
N/A